Cancer Therapeutics
The Cancer Therapeutics Program (CRX) is designed to advance translation of discoveries to the clinic. CRX brings together all investigator-initiated clinical trials (Aim 3) as well as preclinical development of cancer immunology and immunotherapy (Aim 1) and cancer imaging, drug delivery, and image-based technologies (Aim 2).
Key goals of CRX are to identify promising new discoveries and technologies and then to support collaborations and other opportunities to bring these technologies to clinical trials, licensing, and clinical development. The ultimate goal of this program is to reduce the burden of cancer in the catchment area and beyond, especially for cancers of high incidence or mortality in the catchment area (breast, colorectal, lung, and melanoma).
CRX Program Aims
To accomplish its goals, the research of the CRX program is organized around three specific aims:
- Aim 1: Elucidate the tumor immune landscape and derive new immunotherapies
- Aim 2: Develop novel strategies for therapeutic delivery, combinations, and imaging
- Aim 3: Conduct investigator-initiated therapeutic and imaging clinical trials
The CRX program is led by:
-
-
Kimberly Kelly, PhD
Professor of Biomedical Engineering
-
-
Richard J. Price, PhD
Professor of Biomedical Engineering
-
-
Benjamin W. Purow, MD
Professor of Neurology
The CRX program’s co-leads offer expertise in nanoparticle techniques for diagnostic imaging, focused ultrasound, drug target identification and drug delivery, as well as neuroimmunology and novel therapeutic approaches to brain cancers.